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ABSTRACT 
Background and objective Natalizumab-associated progressive multifocal 
leukoencephalopathy (NTZ-PML) patients may show imaging signs suggestive of 
inflammation at diagnosis (“inflammatory PML”), reminiscent of PML-immune reconstitution 
inflammatory syndrome (PML-IRIS). We investigated the imaging characteristics of 
inflammatory NTZ-PML lesions and PML-IRIS to determine differentiating and overlapping 
features. 
Methods  We scored the presence, localization and pattern of imaging characteristics of 
inflammation on brain MRI scans of inflammatory NTZ-PML patients. The imaging 
characteristics were followed-up until the occurrence of PML-IRIS. 
Results 10 out of the 44 NTZ-PML patients included showed signs suggestive of 
inflammation at time of diagnosis. The inflammation pattern at diagnosis was similar to the 
pattern seen at PML-IRIS, with contrast-enhancement representing the most frequent sign of 
inflammation (90% at diagnosis, 100% at PML-IRIS). However, the severity of inflammation 
differed, with absence of swelling and low frequency of perilesional edema (10%) at 
diagnosis, as compared to the PML-IRIS stage. 
Conclusion Patterns of inflammation at the time of PML-diagnosis and at the PML-IRIS 
stage overlap, but differ in their severity of inflammation. This supports histopathological 
evidence that the inflammation seen at both stages of the same disease share a similar 
underlying pathophysiology, representing the immune response to the JC virus to a variable 
extend.  
INTRODUCTION 
Progressive multifocal leukoencephalopathy (PML) is a serious side effect of 
immunosuppressive therapies particularly seen in multiple sclerosis (MS) patients treated 
with natalizumab (NTZ, Biogen Inc, Cambridge, MA, USA), a humanized monoclonal 
antibody against the α4-integrin adhesion molecule.[1,2] PML is an opportunistic infection of 
the central nervous system (CNS) caused by reactivation and replication of JC virus (JCV), 
characterized by a lytic infection of oligodendrocytes, astrocytes and neuronal cells.[3-5] 
PML risk mitigation programs during therapy with NTZ recommend regular clinical 
assessment, laboratory tests (eg, JCV serostatus), and magnetic resonance imaging (MRI), 
aiming at improving the benefit-risk ratio of a drug with a known high clinical and MRI efficacy 
in MS.[6-9]  
In NTZ-treated MS patients, brain MRI can detect opportunistic infections such as 
PML at very early stages, even prior to the development of clinical symptoms suggestive of 
PML coining the term presymptomatic or asymptomatic PML.[10-14] However, the detection 
of PML at an early stage can be challenging since the imaging findings can be subtle, 
fluctuating and difficult to interpret.[15-19] In comparison to classical, human 
immunodeficiency virus (HIV) associated cases of PML, NTZ-PML  displays a higher 
frequency of MR imaging signs suggestive of inflammation at time of diagnosis, including 
contrast-enhancement and punctuate lesions with a perivascular distribution pattern, 
reported in approximately 30% of the patients [11,15,16]. Such lesions can be the most 
prominent initial imaging sign at the time of PML diagnosis, even in asymptomatic NTZ-PML, 
reflecting inflammation in the perivascular spaces and thereby unmasking the opportunistic 
infection.[19-22] These observations have led to the term “inflammatory PML”, thereby 
differentiating these PML cases from those without any signs of inflammation, termed 
“classical PML”.[18,23,24] It has been suggested that the inflammation in NTZ-PML is 
caused by the mode of action of a drug that is classified as a selective immune suppressant, 
with a partial maintenance of immune functions in the central nervous system.[25]  
“Inflammatory PML” shares several imaging and histopathological characteristics with 
PML- immune reconstitution inflammatory syndrome (IRIS). [20,21]  PML-IRIS is 
characterized by a clinical deterioration despite partial or full recovery of the immune 
competence in previously immune-compromised patients.[22,26-30] Inflammatory PML and 
PML-IRIS often are not clearly separated, and terminology is partly conflicting in published 
literature. In “inflammatory PML”, lytic infection by JCV is supposed to be the leading cause 
of structural brain damage, and inflammation a rather desirable side action of a still partly 
functioning immune system limiting the further spread of, and supporting the destruction by 
the virus. In contrast, during PML-IRIS, the immune reactions, initiated by the JCV replicating 
but then spreading and becoming an independent factor of tissue destruction, is believed to 
overshoot and become the leading cause of structural brain damage. Thus, the correct 
interpretation and recognition of the two distinct variants of inflammation could affect 
management and treatment of patients with PML.[31,32]  
Systematic data on the lesion evolution of inflammatory PML lesions, and criteria for 
separation from PML-IRIS are lacking. The aim of this study was to investigate 
characteristics of inflammatory PML and PML-IRIS, including the lesion evolution in patients 









PATIENTS AND METHODS 
Standard protocol approvals, registrations, and patient consents 
Brain MRI is included in the standard patient care of NTZ-treated MS patients for 
treatment efficacy assessment and safety monitoring purposes. We retrospectively collected 
clinical, laboratory and imaging data from NTZ-PML patients. We obtained a waiver from our 
local institutional review board stating that the requirements of the Medical Research 
Involving Human Subjects Act did not apply and that official IRB approval was not 
mandatory. Written informed consent was obtained from all participants for the use of the 
clinical, laboratory and imaging data for research and teaching purposes. 
 
Study design, patient selection 
This retrospective study used routine brain MR images for the diagnosis and follow-
up of PML lesions in NTZ-treated MS patients. We obtained data from 67 natalizumab-
associated PML patients, 25 of whom were derived from the Dutch-Belgian natalizumab-
associated PML cohort and 42 patients referred by other institutions to our center for second 
opinion and research purposes. Figure 1 gives detailed information on the patient selection 
and inclusion process. MR images were collected in the Digital Imaging and Communication 
in Medicine (DICOM 3) file format. All MRI scans from the first observation of PML lesions 
through follow-up until and including PML-IRIS stage were collected. Only patients fulfilling 
the following criteria were analyzed for the purpose of this study: 1. Availability of T2-
weighted and contrast-enhanced T1-weighted images at the time of diagnosis, and during 
PML follow-up. 2. MR images of sufficient quality, suitable for diagnostics purposes (i.e., no 
movement artefacts or bad repositioning etc.). 3. Sufficient data available at diagnosis and 
during the clinical course to enable assessment of the detection of imaging findings 
suggestive of PML-IRIS.[33]  
 
 
Image analysis and interpretation 
All MRI scans were analyzed on a digital workstation in consensus by two raters 
(MPW, MTW) with special expertise in the field of inflammatory diseases of the CNS. Brain 
MRI scans were screened for signs suggestive of inflammation at the time of PML diagnosis, 
before immune reconstitution (“inflammatory PML”).  
Imaging characteristics suggestive of inflammation were categorized as recently 
described [33]: 1. Occurrence of contrast enhancement in the brain. 2. Occurrence of lesions 
showing new signs of mass effect and/or perilesional edema. Per definition: subtle 
perilesional edema can present without any mass effect or swelling. 3. Occurrence of new 
punctate T2 lesions with a perivascular spread. The characteristics of contrast-enhancement 
were further classified according to the localization (in the center of PML lesions, in the 
border of PML lesions, outside of PML lesions with a perivascular spread, or outside of PML 
lesions without a perivascular spread), and the enhancement pattern (punctuate, 
homogeneous, patchy).  
In patients showing signs of inflammation at the time of PML diagnosis, the evolution 
of MRI findings were assessed on follow-up MRI scans up to, and including PML-IRIS stage. 
Patients were considered to fulfill the PML-IRIS stage when both clinical deterioration, and 
new or progressive imaging signs of inflammation were noted on MRI after NTZ 
cessation.[23,26,27,33]  The MRI analysis on the follow-up visits included: 1: Lesion 
evolution of the main PML lesions (size increase, decrease, stable). 2. contrast-
enhancement: increase, decrease or stable contrast-enhancement of pre-existing lesion, 
new contrast-enhancing lesion, change of the enhancement pattern. 3. New small T2 lesions 
with a perivascular distribution pattern 4. New mass effect and/or edema.  
 
MRI protocols 
Since the PML cases were collected from different centers, the image acquisition 
parameters including pulse sequences, head coils and magnetic field strengths (1.5T and 
3T) and parameters related to spatial resolution were heterogeneous and based on local MRI 
protocols. In all patients the MRI protocol at the time of first PML lesion detection and during 
follow-up, including the PML-IRIS stage, consisted of T2-weighted, T2-fluid attenuated 
inversion recovery (FLAIR), and post-contrast T1-weighted MR images. In 17 patients, pre-
contrast T1-weighted images were also available during follow-up. Based on the multi-center 
data acquisition, the scan intervals of follow-up MRI after the diagnosis of PML were not 
standardized and ranged from 1 to 4 weeks.   
RESULTS 
Patients 
Of the screened 67 natalizumab-associated PML patients, 44 patients were eligible 
for analysis. Nineteen patients were excluded due to insufficient data available during follow-
up of the PML disease course and two were excluded due to insufficient data available at 
PML diagnosis (inclusion criterion 3). Two patients were excluded due to insufficient quality 
of the MR images (inclusion criterion 2). Among the included patients, only the 10 patients 
that showed imaging signs of inflammation at the time of PML diagnosis were selected for 
the purpose of this study (figure 1). The demographic and clinical information of these 10 
patients are presented in table 1, including the diagnostic classification according to PML 
diagnostic criteria as proposed in a consensus statement from the American Academy of 
Neurology (AAN) Neuroinfectious Disease Section [34]. 
 With respect to the treatment history before the initiation of natalizumab, in 7 of the 
10 patients, exact data on prior immunotherapy for the treatment of MS prior to NTZ-PML 
development is known. Four were previously treated with interferon beta-1a, one had been 
treated interferon beta-1a and interferon beta-1b, and two had no prior immunotherapy. Of 
the remaining three patients, it is known that they were not previously treated with 
immunosuppressive therapy, but it is unknown whether they had used immunomodulatory 
drugs. 
  
Imaging characteristics of inflammation at PML diagnosis and during PML-IRIS phase 
Global frequency of imaging signs of inflammation 
As per definition, all patients analyzed showed signs of inflammation already at time 
of PML diagnosis, with contrast enhancement seen in 9 out of 10 patients (90%), and 
perivascular T2 lesions in 6 patients (60%), among whom one did not display contrast 
enhancement. At the time of PML-IRIS, all patients (100%) displayed contrast enhancement, 
and the proportion of patients with perivascular T2 lesions increased to 8 out of the 10 
patients (80%). Perilesional edema was seen in only 1 patient at time of diagnosis (10%), 
increasing to 4 (40%) during PML-IRIS. Swelling with mass effect was absent in patients at 
diagnosis, increasing to 6 (60%) during PML-IRIS.  
Characteristics of contrast enhancement 
 At PML diagnosis and during PML-IRIS, contrast enhancement was seen at the 
border of the PML lesion (8 and 10 patients, respectively), outside of the PML-lesions (6 and 
9 patients, respectively), and in the center of the PML lesion (2 and 5 patients, respectively). 
 Appearance of contrast enhancement was rarely noted to be homogenous (none at 
diagnosis, 1 during PML-IRIS), but either of punctate (5 at diagnosis, 8 during PML-IRIS), or 
of patchy (8 at diagnosis, 10 during PML-IRIS). Figures 2 and 3 show examples of different 
enhancement pattern (punctuate, patchy). 
 
Individual course of the patients and MRI lesion characteristics 
The individual course of lesion characteristics of the patients is shown in table 2. The 
clinical presentation including EDSS has not been systematically assessed during and after 
the PML/PML-IRIS disease course. One single patient (patient number 1) died, all other 
patients survived PML/PML-IRIS. One patient (patient number 7) stayed asymptomatic 
during the whole PML/PML-IRIS disease course. One patient (patient number 1) received 
single course of i.v. corticosteroids (1000 mg/day for three days) directly after the diagnosis 
of inflammatory PML.  
Comparing extent and distribution of contrast enhancement at diagnosis and at the 
PML-IRIS stage, nine out of ten patients showed new or persisting contrast-enhancement 
following the same pattern during PML-IRIS as seen at the time of PML diagnosis (seven 
patients with new contrast-enhancing lesions following a similar pattern and seven patients 
with persistence of the contrast enhancement from the time of diagnosis). The progression of 
contrast-enhancement at/during PML-IRIS stages was present in the center/at the border of 
the main lesion as well as in lesions outside the main PML lesion (Figure 3). In the one 
patient showing just perivascular T2 lesion as imaging sign suggestive of inflammation at the 
time of PML diagnosis, these perivascular T2 lesions started showing additional contrast 
enhancement, with associated edema and mass effect in other locations during the PML-
IRIS phase. Figure 2 and 3 show examples of the inflammatory PML lesion characteristics at 




In this study, we systematically describe the imaging characteristics of “inflammatory 
PML” lesions, and we show that the vast majority of these patients continue to show similar 
signs of inflammation during PML-IRIS stages. Signs of inflammation, in particular contrast-
enhancement, seen on brain MRI have been described in approximately 30% of 
natalizumab-associated PML patients at the time of PML diagnosis, either in symptomatic or 
asymptomatic disease stages.[11,15,16,35] The pathophysiological background of these 
imaging signs suggestive of inflammation remained poorly understood for a long time. 
Recent histopathological data suggested that such inflammation at the time of PML diagnosis 
might be related to an immune response against the JC virus, similar to, but less severe 
than, in patients entering the PML-IRIS stage.[23,26,27] PML-IRIS lesions are characterized 
by inflammatory cell infiltrations including an abundance of CD8+ T cells and numerous 
macrophages. In addition, surprisingly high plasma cell numbers were reported in 
natalizumab-associated PML-IRIS by one histopathological case series, not noted in HIV 
associated PML.[27] Of importance to our study, natalizumab-associated inflammatory PML 
cases generally share  these histopathological findings of PML-IRIS, including the high 
plasma cell numbers, albeit to a lesser extent.[27]  This also refers to specific patters of 
inflammation, such as the observation of perivascular cuffing, observed PML-IRIS patients as 
well as in inflammatory PML patients.[26] Obviously, even in early PML stages, CD8+ 
cytotoxic T cells are able to attack the JC virus and control the PML disease activity.[36]      
In fact, our in-vivo imaging study is in line with these histopathological data. In 
general, the vast majority of our patients showed a similar imaging pattern of inflammation at 
the time of PML diagnosis as during the PML-IRIS stage. Although the imaging pattern 
suggestive of inflammation remained similar during follow-up, the severity of inflammation 
increased at the PML-IRIS stage including new enhancing lesions, swelling, and perilesional 
edema. As such, imaging patterns of inflammation at the time of PML diagnosis and at the 
PML-IRIS stage likely are no distinct entities, but rather differ in their extent of inflammation. 
This supports experimental evidence that the inflammation seen at both stages of the same 
disease may share a similar underlying pathophysiology, representing the immune response 
to the causative JC virus to a variable extend.[27]   
Comparing our present inflammatory PML patients to our recently published ‘classic’ 
NTZ-PML cohort without any imaging signs of inflammation, the time interval between PML 
diagnosis and PML-IRIS occurrence was longer for patients with “inflammatory” PML (66.5 
days, range: 23-224 [table 1] versus 42 days, range 6-98 days). In addition, one of our 
inflammatory PML patients received i.v. corticosteroids directly of the diagnosis of 
inflammatory PML whereas 4 patients of the non-inflammatory PML cohort received 
corticosteroids < 30 days to PML-IRIS manifestation.[33] It remains unclear if this difference 
holds up in independent cohorts, and if this is of clinical relevance. However, it could have 
influenced the patient management.[37]  
 In general, the investigation of any link between the clinical outcome and the 
described MRI findings was not the aim of this study. Owing to the rather small size of our 
study, we were unable to link presence or absence of inflammation at time of PML diagnosis 
to clinical outcome, warranting larger studies and a prospective, multicentric approach. 
Furthermore, another open question is if patients with signs of inflammation on imaging 
should be treated differently as compared to patients with classical PML. Potential 
differences in the patient management could relate to the early administration of 
corticosteroids even before the patient is classified as PML-IRIS, or the use of measures of 
enhancing NTZ clearance depending on imaging characteristics (plasmapheresis/ 
immunoabsorption). Additional biomarkers such as virus specific antibody responses in 
blood, CSF, or T cell responses that classify and quantify the immune response against JCV 
at the time of PML diagnosis may potentially be useful tools for individualizing therapeutic 
regimens.[31,32,38,39]   
This study has limitations. First of all, the number of patients in our study presenting 
with imaging signs suggestive of inflammation with a complete clinical and radiological 
follow-up until the PML-IRIS stage is rather small. Although these patients are well 
characterized in terms of patient management, treatment and co-morbidity, we cannot 
exclude that some of these aspects could have influenced the clinical and imaging 
presentation. Further studies including larger numbers of patients are needed to further 
support our results. 
In conclusion, our study demonstrates that an imaging pattern suggestive of 
inflammation at the time of PML diagnosis in natalizumab-treated MS patients shares 
imaging characteristics of PML-IRIS in later disease stages. Many of these initial 
inflammatory PML lesions develop into sites of severe inflammation at PML-IRIS stage. This 
further supports histopathological and experimental data that this inflammation at the time of 
PML diagnosis is most likely based on a  lymphocytic response against the JC virus due to 




The authors wish to thank all PML patients for agreeing to the use of their MRI images and 
(para)clinical data for research and education purposes. In addition, we wish to thank 
Professor Wolfgang Brück and Dr. Imke Metz (Department of Neuropathology, University 
Hospital Göttingen, Germany) for sharing their data and expertise on histopathology findings 
in natalizumab-associated PML-IRIS. FB is supported by the NIHR biomedical research 
centre at UCLH. 
 
Funding 
The MS Centre Amsterdam is funded by a program grant (14-358e) from the Stichting voor 




MPW, MTW collected the data, analyzed the data and wrote the manuscript. FB, SF, BMJU, 
CW and JK interpreted the data and edited the manuscript. All authors reviewed and agreed 
on the final versions of the manuscript. 
 
Competing interest 
MPW has received consultancy fees from Biogen, Novartis and Roche. FB serves as a 
consultant for Bayer-Schering Pharma, Sanofi-Aventis, Biogen, Teva, Novartis, Roche, 
Synthon BV, Genzyme, Jansen Research. JK has accepted consulting fees from Merck-
Serono, TEVA, Biogen, Genzyme, and Novartis. BMJU has received consultancy fees from 
Novartis, Merck Serono, Biogen and Danone Research. MTW does not report any competing 
interest. The VUmc has received financial support for research activities from Bayer Schering 
Pharma, Biogen, Glaxo Smith Kline, Merck Serono, Novartis, and Teva. JE received 
consultancy fees and/ or lecture fees from Biogen, Genzyme, Teva, Merck and Novartis. The 




Bob W van Oosten and Chris H. Polman (VU University Medical Center, Amsterdam, The 
Netherlands), Dorine A Siepman and Rogier Hintzen (Erasmus MC, University Medical 
Center Rotterdam, The Netherlands), Jop Mostert (Rijnstate Hospital, Department of 
Neurology, Arnhem, The Netherlands), Wibe Moll (Maasstad Hospital, Rotterdam, The 
Netherlands), Alex EL van Golde (ZGT Hospital, Almelo, The Netherlands), Stephan TFM 
Frequin (St Antonius Hospital, Nieuwegein, The Netherlands), Paul AD Bouma (Tergooi, 
Blaricum, Hilversum, The Netherlands), Bénédicte Quivron (CH Jolimont, La Louvière, 
Belgium), Jean Braeckeveldt (Epicura, Baudour, Belgium),  Erik van Munster and Jeroen van 
Eijk (Department of Neurology, Jeroen Bosch Ziekenhuis, ’s Hertogenbosch, The 
Netherlands), Thea Heersema (Department of Neurology, University Medical Center 







1. Maas RP, Muller-Hansma AH, Esselink RA, et al. Drug-associated progressive 
multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid 
analysis of 326 cases. J Neurol 2016;263:2004-21. 
2. Rudick R, Polman C, Clifford D, Miller D, et al. Natalizumab: bench to bedside and 
beyond. JAMA Neurol 2013;70:172-182. 
3. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders 
caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9:425-
437. 
4. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal 
leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 2010;6: 
667-79. 
5. Wijburg MT, van Oosten BW, Murk JL, Karimi O, Killestein J, Wattjes MP. 
Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): 
a case series and review of the literature. J Neurol 2015;262:65-73. 
6. Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease-
modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 
2016;12:217-33. 
7. Wattjes MP, Rovira À, Miller D, et al. Evidence-based guidelines: MAGNIMS 
consensus guidelines on the use of MRI in multiple sclerosis--establishing disease 
prognosis and monitoring patients. Nat Rev Neurol 2015;11:597-606. 
8. McGuigan C, Craner M, Guadagno J,et al. Stratification and monitoring of 
natalizumab-associated progressive multifocal leukoencephalopathy risk: 
recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016;87:117-
25. 
9. Vågberg M, Axelsson M, Birgander R, et al. Guidelines for the use of magnetic 
resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: 
recommendations of the Swedish Multiple Sclerosis Association and the Swedish 
Neuroradiological Society. Acta Neurol Scand 2017;135:17-24. 
10. Linda H, Von HA. Presymptomatic diagnosis with MRI and adequate treatment 
ameliorate the outcome after natalizumab-associated progressive multifocal 
leukoencephalopathy. Front Neurol 2013;4:11. 
11. Wattjes MP, Vennegoor A, Steenwijk MD, et al. MRI pattern in asymptomatic 
natalizumab-associated PML. J Neurol Neurosurg Psychiatry 2015;86:793-8. 
12. Dong-Si T, Richman S, Wattjes MP, et al. Outcome and survival of asymptomatic 
PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 2014;1:755–764. 
13. Mc Govern EM, Hennessy MJ. Asymptomatic progressive multifocal 
leukoencephalopathy associated with natalizumab. J Neurol 2013;260:665–7. 
14. Hodel J, Outteryck O, Dubron C, et al. Asymptomatic Progressive Multifocal 
Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR 
Imaging. Radiology 2016;278:863-72. 
15. Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in 
natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 
2012;72:779–87. 
16. Richert N, Bloomgren G, Cadavid D, et al. Imaging findings for PML in natalizumab-
treated MS patients. Mult Scler 2012;18(Suppl 4):27–8. Oral 99. 
17. Wattjes MP, Vennegoor A, Mostert J, et al. Diagnosis of asymptomatic natalizumab-
associated PML: are we between a rock and a hard place? J Neurol 2014;261:1139–
43. 
18. Wattjes MP, Richert ND, Killestein J, et al. The chameleon of neuroinflammation: 
magnetic resonance imaging characteristics of natalizumab-associated progressive 
multifocal leukoencephalopathy. Mult Scler 2013;19:1826-40. 
19. Wattjes MP, Wijburg MT, Vennegoor A, et al. Diagnostic performance of brain MRI in 
pharmacovigilance of natalizumab-treated MS patients. Mult Scler 2016;22:1174-83. 
20. Phan-Ba R, Lommers E, Tshibanda L, et al. MRI preclinical detection and 
asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under 
natalizumab therapy. J Neurol Neurosurg Psychiatry 2012;83:224–226. 
21. Wattjes MP, Verhoeff L, Zentjens W, et al. Punctate lesion pattern suggestive of 
perivascular inflammation in acute natalizumab-associated progressive multifocal 
leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS 
manifestation? J Neurol Neurosurg Psychiatry 2013;84:1176-7. 
22. Hodel J, Darchis C, Outteryck O, et al. Punctate pattern: A promising imaging marker 
for the diagnosis of natalizumab-associated PML. Neurology 2016;86:1516-23. 
23. Clifford DB. Neurological immune reconstitution inflammatory response: riding the tide 
of immune recovery. Curr Opin Neurol 2015;28:295-301. 
24. Wattjes MP, Barkhof F. Diagnosis of natalizumab-associated progressive multifocal 
leukoencephalopathy using MRI. Curr Opin Neurol 2014;27:260-70 
25. Schneider-Hohendorf T, Rossaint J, Mohan H, et al. VLA-4 blockade promotes 
differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-
adhesion of TH17 cells. J Exp Med 2014;211:1833-46. 
26. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update 
on PML and PML-IRIS occurring in multiple sclerosis patients treated with 
natalizumab. J Neuropathol Exp Neurol 2012;71:604-17. 
27. Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory 
syndrome in multiple sclerosis with natalizumab-associated progressive multifocal 
leukoencephalopathy. Acta Neuropathol 2012;123:235–245. 
28. Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome 
in natalizumab-associated PML. Neurology 2011;77:1061–1067. 
29. Gheuens S, Smith DR, Wang X, et al. Simultaneous PML-IRIS after discontinuation of 
natalizumab in a patient with MS. Neurology 2012;78:1390–1393. 
30. Post MJ, Thurnher MM, Clifford DB, et al. CNS-immune reconstitution inflammatory 
syndrome in the setting of HIV infection, part 1: overview and discussion of 
progressive multifocal leukoencephalopathy-immune reconstitution inflammatory 
syndrome and cryptococcal-immune reconstitution inflammatory syndrome. AJNR Am 
J Neuroradiol 2013;34:1297-307. 
31. Antoniol C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell response by 
corticotherapy: effect on PML-IRIS management. Neurology 2012;79:2258–64. 
32. Berger JR. Steroids for PML-IRIS: a double-edged sword? Neurology 
2009;72(17):1454-5. 
33. Wattjes MP, Wijburg MT, Vennegoor A, et al. MR imaging characteristics of early 
PML-IRIS after natalizumab-treatment in MS patients. J Neurol Neurosurg Psychiatry 
2016;87:879-84. 
34. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: Consensus 
statement from the AAN Neuroinfectious Disease Section. Neurology 2013;80:1430–
8. 
35. Post MJ, Yiannoutsos C, Simpson D, et al. Progressive multifocal 
leukoencephalopathy in AIDS: are there any MR findings useful to patient 
management and predictive of patient survival? AIDS Clinical Trials Group, 243 
Team. AJNR Am J Neuroradiol 1999;20:1896-906. 
36. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacque J, Letvin NL, Koralnik IJ. A 
prospective study demonstrates an association between JC virus-specific T 
lymphocytes and the early control of progressive multifocal leukoencephalopathy. 
Brain 2004; 127: 1970-1978 
37. Hoepner R, Kolb EM, Dahlhaus S, et al. Predictors of severity and functional outcome 
in natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 
2017;23:830-835. 
38. Warnke C, von Geldern G, Markwerth P, et al. Cerebrospinal fluid JC virus antibody 
index for diagnosis of natalizumab-associated progressive multifocal 
leukoencephalopathy. Ann Neurol 2014;76:792-801. 
39. Warnke C, Wijburg MT, Hartung HP, Killestein J, Adams O, Wattjes MP. Application 
of the CSF JCV antibody index to early natalizumab-associated progressive multifocal 
leukoencephalopathy. J Neurol Neurosurg Psychiatry 2017 May 10, doi: 














Legends to the figures: 
 
Figure 1 
Flow chart illustrating the patient selection and inclusion process.  
 
Figure 2 
T2 and T1 weighted images (with contrast administration) at the time of PML diagnosis (top 
row) and at the time of PML-IRIS stage (bottom row). The images at diagnosis (“inflammatory 
PML”) show a subcortical and cortical lesion in the right frontal lobe showing contrast 
enhancement (C, D) in addition to punctuate T2 lesions following a perivascular distribution 
that also enhance on T1 after contrast administration (A, B). These inflammatory PML 
lesions show different enhancement pattern such as punctuate (B) and patchy (D). At the 
time of PML-IRIS manifestation the PML lesions have increased in size and the contrast 
enhancement of the main PML lesion (H, I) as well as in and around the perivascular T2 
lesions (F, G) has also markedly increased. In addition, there are now signs of edema with 
mass effect around the PML lesions (F, H).  
 
Figure 3 
Fluid attenuation inversion recovery (FLAIR), T2 and T1 weighted images (with contrast 
administration) at the time of PML diagnosis (top row), and at the time of PML-IRIS stage 
(bottom row). At the time of diagnosis there are multiple contrast enhancing punctuate T2 
lesions (punctuate enhancement pattern) with a perivascular distribution visible (A – C). At 
PML-IRIS manifestation there is a massive increase in the number of contrast enhancing 
perivascular lesions and persistence of the contrast enhancement from the time of diagnosis 
(D – F). The increase of punctuate lesions in number and size includes enhancing lesions in 
the main PML lesions as well as outside of the main PML lesion (F). In addition, the main 
PML lesion had increased in size. 
  
Table 1: Demographic and clinical characteristics of the included patients 
Demographic and clinical information of the study participants Median [range] 
Gender (female), n (%) 7 (70%) 
Age (years)1 40 [23 – 55] 
Natalizumab treatment duration (doses) at PML diagnosis 44 [12 – 63] 
Interval first inflammatory PML MRI scan until last natalizumab administration, in 
days1 (for patients in whom natalizumab was continued because inflammatory PML 
lesions were not recognized as PML lesions; four cases)  
38 [3 – 172] 
Interval last natalizumab administration until first inflammatory PML MRI1 (five 
cases) 
20 [3 – 36] 
Asymptomatic* at the time of PML diagnosis*, n (%) 2 (20%) 
Symptomatic at the time of PML diagnosis, n (%) 8 (80%) 
“Definite PML”** at the time of PML diagnosis#, n (%) 7 (70%) 
“Probable PML”** at the time of PML diagnosis#, n (%) 0 (0%) 
“Possible PML”** at the time of PML diagnosis#, n (%) 1 (10%) 
“Not PML”** at the time of PML diagnosis#, n (%) 2 (20%) 
“Definite PML”** during the observational period#, n (%) 7 (70%) 
“Probable PML”** during the observational period#, n (%) 0 (0%) 
“Possible PML”** during the observational period#, n (%) 3 (30%) 
“Not PML”** during the observational period#, n (%) 0 (0%) 
Patients who received corticosteroids prior to PML diagnosis 
Patients who received corticosteroids directly after PML diagnosis 
0 (0%) 
1 (10%) 
Interval between PML diagnosis and PML-IRIS in days during follow-up  66.5 [23 – 224] 
PML=progressive multifocal leukoencephalopathy, IRIS= immune reconstitution inflammatory 
syndrome 
1 data missing for one patient. 
* Asymptomatic PML is defined as no symptoms suggestive of PML 
** “Definite PML”: all patients had a clinical presentation and imaging findings suggestive of PML as 
well as JCV DNA in the CSF detected by PCR. “Probable PML”: all patients were asymptomatic, had 
MRI lesion(s) suggestive of PML and JCV DNA in the CSF detected by PCR. “Possible PML”:  all 
patients had clinical symptoms suggestive of PML and MRI lesion(s) suggestive of PML but no JCV 
DNA detected in the CSF. “No PML”: all patients had MRI lesion(s) suggestive of PML but no clinical 
symptoms suggestive of PML, no JCV DNA has been detected in the CSF. 


















Patient PML diagnosis (n=10) PML-IRIS stage (n=10) Findings at PML-IRIS phase 
      Persistence 
of 
enhancement 





























or mass effect 
1 Contrast enhancement in border of the 
PML lesions and enhancing perivascular 
T2 lesions 
Persistent enhancing lesions from PML 
diagnosis. New enhancing lesions with a 
similar pattern. 
y y N Y n n 
2 Contrast enhancement in the center and 
border of the PML lesions 
Persistent enhancing lesions from PML 
diagnosis. New enhancing lesions with a 
similar pattern and enhancing 
perivascular T2 lesions. 
y y Y - y n 
3 Contrast enhancement in the border of 
the PML lesions and enhancing 
punctuate T2 lesions adjacent to the 
Enhancement from time of diagnosis 
disappears during follow-up. New 
contrast enhancing lesions following-
same pattern as at diagnosis, plus 
n y n Y y y 
main PML lesion swelling with mass effect. 
4 Punctuate contrast enhancement 
adjacent to the main PML lesion and 
with a perivascular spread 
Persistent enhancing lesions from PML 
diagnosis. New enhancing lesions in the 
border of the PML lesions, plus swelling 
with mass effect. 
y n Y Y n y 
5 Contrast enhancement in the border of 
the PML lesions and adjacent to the 
PML lesions  
Persistent enhancing lesions from PML 
diagnosis. New enhancing lesions with a 
similar pattern and new enhancing 
lesions in the center of the PML lesions 
plus swelling with mass effect. 
y y Y - n y 
6 Contrast enhancement in the center, 
border and outside of the PML lesions, 
enhancing punctuate T2 lesions and 
perilesional edema 
Persisting enhancement and edema. 
New enhancing lesions with a similar 
pattern and swelling with mass effect. 
y y N Y n y 
7 Contrast enhancement in the border and 
outside of the PML lesion with 
enhancing perivascular T2 lesions 
Persisting enhancement. New 
enhancing lesions with a similar pattern 
and new enhancing lesions outside of 
PML lesions, and new perilesional 
edema and swelling with mass effect. 
y y Y Y n y 
8 Contrast enhancement in the border of 
the PML lesion with enhancing 
perivascular T2 lesions 
Enhancement from time of diagnosis 
disappears during follow-up. New 
contrast enhancing lesions following-
same pattern as at diagnosis and new 
enhancing lesions in the center and 
outside of the PML lesion, plus 
perilesional edema. 
n y Y Y n y 
9 Contrast enhancement in the border of 
the PML lesion 
Slight diminishment of earlier 
enhancement, new punctuate enhancing 
lesions outside of the PML lesion 
y/n n Y - n n 
10 Perivascular T2 lesions Contrast enhancement of perivascular 
T2 lesions and enhancement in border 
and outside of the PML lesion, plus 
perilesional edema and swelling with 
mass effect 
- - Y Y y y 
PML: progressive multifocal leukoencephalopathy, IRIS: immune reconstitution inflammatory syndrome. Dx: diagnosis, y: yes, n: no, n/a: not 
applicable. 
 
